The Samsung Biologics labor union began its first full-scale strike on May 1, 2026 [2].
This walkout represents a significant escalation in labor tensions at one of South Korea's primary biotechnology hubs. Because the company relies on precise manufacturing timelines to maintain global contracts, a total stoppage of work could disrupt the delivery of critical biologic medicines.
The decision to strike followed a vote in which 95.52 percent of union members, totaling 3,351 votes, supported the action [1]. This overwhelming majority indicates a deep rift between the workforce and management regarding the current direction of the company.
Union leaders said the strike was triggered by a need to protect order-winning competitiveness. The union is seeking to improve negotiation terms, and has expressed concerns over future contracts and internal company policies [3].
While Samsung Biologics has grown rapidly as a contract development and manufacturing organization, the union said current policies threaten the long-term stability of the workforce. The strike is intended to force the company to address these structural concerns during upcoming negotiations [3].
The walkout affects facilities located within South Korea [4]. The union has not specified a date for the conclusion of the strike, though they said that a return to work depends on the company's willingness to meet their demands [3].
“The Samsung Biologics labor union began its first full-scale strike on May 1, 2026.”
This strike marks a pivotal shift in the labor dynamics of South Korea's biotech sector, where Samsung Biologics holds a dominant market position. By striking over 'order-winning competitiveness,' the union is signaling that labor stability is now directly tied to the company's ability to secure and maintain global pharmaceutical contracts. Any prolonged disruption may prompt international clients to diversify their manufacturing sources to avoid supply chain risks.
